Broncus Holding Corporation (BRNHF)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in USDTTM unavailable| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 3 | 11 | 9 | 10 | 8 | 0 | - | - |
| Operating profit | $m | -24 | - | ||||||
| Net profit | $m | -48 | -235 | -28 | -28 | -15 | -18 | - | - |
| EPS reported | $ | -0.04 | - | ||||||
| Operating cashflow per share | $ | -0.02 | - | ||||||
| Capex per share | $ | 0.00 | - | ||||||
| FCF per share | $ | -0.02 | - | ||||||
| Free cash flow | $m | -10 | - | ||||||
| Net debt | $m | -125 | - | ||||||
| Book value equity | $m | 150 | - | ||||||
| Book value per share | $ | 0.31 | - | ||||||
| Number of shares | m | 483.76 | - | ||||||
| DPS (TTM paid) | $ | 0.00 | - |
Financial summary
Financials in USDTTM unavailable| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | - | - | ||||||
| P/B LTM | x | 0.26 | - | ||||||
| P/S LTM | x | 222.09 | - | ||||||
| P/FCF LTM | x | -3.86 | - | ||||||
| EV/EBITDA LTM | x | -0.30 | - | ||||||
| EV/Sales LTM | x | 38.94 | - | ||||||
| Earnings Yield LTM | % | -46.26% | - | ||||||
| FCF Yield | % | -25.93% | - | ||||||
| Quality | |||||||||
| ROE | % | -11.94% | - | ||||||
| ROIC | % | -16.26% | - | ||||||
| Operating margin | % | -140.18% | - | ||||||
| Gross margin | % | -15.85% | - | ||||||
| FCF/Sales | % | -5759.21% | - | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | - | - | ||||||
| Sales Growth YoY | % | -97.86% | - | ||||||
| Net Income Growth YoY | % | - | - | ||||||
| FCF Growth | % | - | - | ||||||
| Operating Profit Growth | % | - | - | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | - | ||||||
| Dividend Growth | % | - | - | ||||||
| Payout Ratio | % | 0.00% | - | ||||||
| FCF/Debt | x | -627.36 | - | ||||||
| Net Debt/EBITDA | x | 1.43 | - | ||||||
| EBIT/Net interest | x | -6,099.15 | - | ||||||
| Net debt/market cap | % | +0.04% | - | ||||||
| Net debt/Equity | x | -0.83 | - | ||||||
| Gross debt/equity | x | 0.00 | - | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
Broncus Holding Corporation is a medical technology enterprise dedicated to advancing interventional pulmonology through the development of specialized products. Its operational reach extends across key markets including Mainland China, the European Union, the United States, and other international regions. The company's product portfolio is broadly categorized into navigation and treatment solutions. Navigation offerings include: LungPoint Virtual Bronchoscopic Navigation: A sophisticated, computer-assisted software system that utilizes imaging for virtual bronchoscopic guidance. LungPoint Plus: This system provides real-time navigational assistance within the airways, crucial for lung biopsies and various other pulmonological procedures. LungPro: A virtual bronchoscopic navigation tool that facilitates three-dimensional, real-time guided transbronchial needle aspiration and features proprietary parenchymal navigation capabilities. Its comprehensive suite of treatment products comprises: InterVapor: A targeted bronchoscopic thermal vapor ablation method designed to treat diseased, hyper-inflated lung segments. RF Generator + RF Ablation Catheter: A radiofrequency ablation system specifically engineered for use with a disposable lung radiofrequency ablation catheter, targeting lung cancer. H-Marker: A specialized marker for pulmonary surgical applications. Furthermore, Broncus provides essential procedural accessories and tools such as: BioStarNeedle: A single-use, ultrasound-guided aspiration needle for efficiently collecting tissue samples. FleXNeedle: A versatile biopsy needle adaptable for multiple purposes. Archimedes Sheath: A sterile, single-use flexible tube that establishes a working channel during bronchoscopic interventions. Archimedes Dilation Balloon: A sterile, single-use flexible tube equipped with a balloon at its tip, inserted via a bronchoscope or sheath to dilate targeted lung tissue within the bronchial tree. Steerable Sheath: Featuring a steerable adjustment handle and a working channel for enhanced maneuverability. Broncus Holding Corporation was established in 2012 and maintains its corporate headquarters in Hangzhou, China.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
No price history available.
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
Broncus Holding Corporation is a medical technology enterprise dedicated to advancing interventional pulmonology through the development of specialized products. Its operational reach extends across key markets including Mainland China, the European Union, the United States, and other international regions. The company's product portfolio is broadly categorized into navigation and treatment solutions. Navigation offerings include: LungPoint Virtual Bronchoscopic Navigation: A sophisticated, computer-assisted software system that utilizes imaging for virtual bronchoscopic guidance. LungPoint Plus: This system provides real-time navigational assistance within the airways, crucial for lung biopsies and various other pulmonological procedures. LungPro: A virtual bronchoscopic navigation tool that facilitates three-dimensional, real-time guided transbronchial needle aspiration and features proprietary parenchymal navigation capabilities. Its comprehensive suite of treatment products comprises: InterVapor: A targeted bronchoscopic thermal vapor ablation method designed to treat diseased, hyper-inflated lung segments. RF Generator + RF Ablation Catheter: A radiofrequency ablation system specifically engineered for use with a disposable lung radiofrequency ablation catheter, targeting lung cancer. H-Marker: A specialized marker for pulmonary surgical applications. Furthermore, Broncus provides essential procedural accessories and tools such as: BioStarNeedle: A single-use, ultrasound-guided aspiration needle for efficiently collecting tissue samples. FleXNeedle: A versatile biopsy needle adaptable for multiple purposes. Archimedes Sheath: A sterile, single-use flexible tube that establishes a working channel during bronchoscopic interventions. Archimedes Dilation Balloon: A sterile, single-use flexible tube equipped with a balloon at its tip, inserted via a bronchoscope or sheath to dilate targeted lung tissue within the bronchial tree. Steerable Sheath: Featuring a steerable adjustment handle and a working channel for enhanced maneuverability. Broncus Holding Corporation was established in 2012 and maintains its corporate headquarters in Hangzhou, China.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free